GO:0047372 monoacylglycerol lipase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0047372 monoacylglycerol lipase activity describes the hydrolysis of a monoacylglycerol into a free fatty acid and glycerol, a reaction catalyzed by enzymes such as MGLL.
• The reaction is central to endocannabinoid signaling because it degrades 2-arachidonoylglycerol (2-AG), a major endogenous cannabinoid receptor ligand.
• Monoacylglycerol lipase activity can be measured in vitro and in situ using radiometric, fluorogenic, and activity-based protein profiling assays.
• Inhibitors of monoacylglycerol lipase are being developed for pain, inflammation, and cancer, with efforts to avoid central side effects and dependence.
• In prostate cancer, monoacylglycerol lipase blockade suppresses the senescence-associated secretory phenotype and improves docetaxel efficacy.
• Marine and microbial monoacylglycerol lipases show biotechnological potential, including soybean oil degumming.
Description
Monoacylglycerol lipase activity (GO:0047372) is a molecular function defined as the catalysis of the reaction: a monoacylglycerol + H2O = a fatty acid + glycerol + H+. This activity is essential for the breakdown of monoacylglycerols, which are intermediates in lipid metabolism and important signaling molecules. The best-characterized enzyme carrying this activity is monoacylglycerol lipase (MGLL), which hydrolyzes 2-arachidonoylglycerol (2-AG), a major endocannabinoid. Because 2-AG modulates pain, inflammation, and neurotransmission, the regulation of monoacylglycerol lipase activity has become a therapeutic target. Beyond mammalian physiology, monoacylglycerol lipases are found in microorganisms and have industrial applications, such as oil degumming. Researchers study this activity to understand lipid signaling, develop inhibitors, and engineer enzymes for biotechnology.
monoacylglycerol lipase activity At A Glance
| GO ID | GO:0047372 |
|---|---|
| GO term | monoacylglycerol lipase activity |
| Ontology | molecular_function |
| Synonym | monoglyceride lipase activity; monoacylglycerol hydrolase activity; acylglycerol lipase activity; monoglyceridase activity |
| Major function | Catalyzes the hydrolysis of monoacylglycerols to free fatty acids and glycerol |
| Reaction | a monoacylglycerol + H2O = a fatty acid + glycerol + H+ |
| Cofactors | No specific cofactors required; water is the nucleophile |
| Subcellular location | Cytosol, membranes, and lipid droplets depending on the enzyme |
| Representative enzyme | MGLL (monoacylglycerol lipase) |
What Is GO:0047372?
In simple terms, monoacylglycerol lipase activity is the ability of an enzyme to cut a monoacylglycerol molecule into two parts: a fatty acid and glycerol. The official GO definition states: Catalysis of the reaction: a monoacylglycerol + H2O = a fatty acid + glycerol + H+. This activity belongs to the molecular_function ontology and is also known by synonyms such as monoglyceride lipase activity, monoacylglycerol hydrolase activity, and acylglycerol lipase activity. It is a hydrolytic reaction that requires water and releases a proton.
Why Is monoacylglycerol lipase activity Important in Cell Biology?
Monoacylglycerol lipase activity is important because it controls the levels of monoacylglycerol signaling lipids, especially 2-arachidonoylglycerol (2-AG), which activates cannabinoid receptors. By degrading 2-AG, monoacylglycerol lipase terminates endocannabinoid signaling, influencing pain, mood, appetite, and inflammation. Inhibiting this activity elevates 2-AG and produces analgesic and anti-inflammatory effects in animal models, but early inhibitors caused central side effects. Newer inhibitors aim to avoid these issues. In cancer, monoacylglycerol lipase activity promotes tumor progression and therapy resistance, making it a potential drug target. Additionally, microbial monoacylglycerol lipases are useful in industrial processes like oil degumming. Thus, understanding this activity spans neuroscience, oncology, and biotechnology.
• Regulates endocannabinoid signaling by degrading 2-arachidonoylglycerol (2-AG).
• Modulates pain perception and inflammation through cannabinoid receptor activation.
• Influences cancer progression and chemotherapy response, as shown in prostate cancer.
• Serves as a target for reversible inhibitors with improved safety profiles.
• Enables spatial mapping of enzyme activity in brain tissue for neurobiology research.
• Provides a tool for oil degumming in food industry using microbial enzymes.
• Plays a role in lipid metabolism and energy homeostasis.
• Assays for its activity are standardized for drug discovery and basic research.
• Its inhibition may offer therapeutic benefits without dependence liability.
• Genetic and pharmacological modulation helps dissect its physiological functions.
What Happens During monoacylglycerol lipase activity?
Substrate binding and recognition
In simple terms: The enzyme grabs a monoacylglycerol molecule from its surroundings.
Monoacylglycerol lipases contain a catalytic serine hydrolase fold that accommodates monoacylglycerols, such as 2-arachidonoylglycerol (2-AG). The enzyme binds the substrate through hydrophobic interactions in the active site, positioning the ester bond for hydrolysis. This step is critical for selectivity, as the enzyme distinguishes monoacylglycerols from di- and triacylglycerols.
Catalytic hydrolysis
In simple terms: Water attacks the ester bond, breaking the molecule into fatty acid and glycerol.
The catalytic mechanism involves a serine-histidine-aspartate triad. The serine nucleophile attacks the ester carbonyl, forming an acyl-enzyme intermediate. Water then hydrolyzes this intermediate, releasing the fatty acid and regenerating the enzyme. Glycerol is also produced, and a proton is released, as summarized in the GO definition. This reaction is highly efficient and can be measured by monitoring the release of fatty acid or glycerol.
Product release and signaling termination
In simple terms: The products leave the enzyme, and the signaling lipid is no longer available to activate receptors.
After hydrolysis, the fatty acid (e.g., arachidonic acid) and glycerol diffuse away. In the endocannabinoid system, this step terminates 2-AG signaling at cannabinoid receptors, thereby modulating synaptic transmission and pain perception. The released arachidonic acid can also serve as a precursor for inflammatory mediators, linking monoacylglycerol lipase activity to inflammation.
Spatial and temporal regulation in tissues
In simple terms: The enzyme works in specific places and times, which can be mapped in the brain.
Monoacylglycerol lipase activity is not uniform across tissues. Recent advances allow spatially resolved mapping of activity in brain sections, revealing distinct patterns that correlate with endocannabinoid signaling domains. This spatial organization ensures precise control of 2-AG levels and downstream effects.
Key Genes Involved in GO:0047372 monoacylglycerol lipase activity
The following genes and proteins are directly associated with monoacylglycerol lipase activity or its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MGLL | Primary enzyme catalyzing monoacylglycerol hydrolysis | Target for inhibitors in pain and cancer; assays for activity |
| ABHD6 | Alternative monoacylglycerol lipase | Contributes to 2-AG degradation in brain; potential drug target |
| ABHD12 | Monoacylglycerol lipase with roles in neuroinflammation | Linked to neurodegenerative disease; studied for inhibitor development |
| FAAH | Fatty acid amide hydrolase, degrades anandamide | Indirectly affects endocannabinoid tone; compared with MGLL |
| CNR1 | Cannabinoid receptor 1 | Mediates effects of 2-AG; downstream of MGLL activity |
| CNR2 | Cannabinoid receptor 2 | Mediates immune effects of 2-AG; relevant to inflammation |
| DAGLA | Diacylglycerol lipase alpha, synthesizes 2-AG | Opposes MGLL; balance regulates endocannabinoid signaling |
| DAGLB | Diacylglycerol lipase beta, synthesizes 2-AG | Contributes to 2-AG production; studied with MGLL |
| PLA2G4A | Phospholipase A2, releases arachidonic acid | Provides substrate for 2-AG synthesis; interacts with MGLL pathway |
| PTGS2 | Cyclooxygenase-2, metabolizes arachidonic acid | Links MGLL activity to prostaglandin synthesis |
| NFKB1 | NF-kappa-B subunit, inflammation regulator | MGLL blockade interferes with NF-kB activation in cancer |
| RELA | NF-kappa-B subunit, inflammation regulator | Part of SASP regulation affected by MGLL inhibition |
| TP53 | Tumor suppressor, senescence regulator | Mutated in cancers; MGLL affects senescence phenotype |
| CDKN1A | p21, cell cycle inhibitor | Senescence marker; modulated by MGLL in prostate cancer |
| IL6 | Interleukin-6, SASP factor | Secreted in senescence; reduced by MGLL blockade |
| CXCL8 | Interleukin-8, SASP factor | Inflammatory cytokine; affected by MGLL inhibition |
| GAPDH | Glyceraldehyde-3-phosphate dehydrogenase | Common loading control in MGLL assays |
| ACTB | Beta-actin | Housekeeping gene for expression studies |
How Is monoacylglycerol lipase activity Regulated?
Monoacylglycerol lipase activity is regulated at multiple levels. Transcriptionally, MGLL expression can be induced by inflammatory stimuli and in cancer cells. Post-translationally, the enzyme can be phosphorylated, although the functional consequences are not fully understood. Activity is also controlled by subcellular localization; MGLL is found in cytosol and membranes, and its access to 2-AG is influenced by lipid droplet dynamics. Pharmacologically, reversible inhibitors such as aryl sulfoxides bind to the active site and block hydrolysis. Natural compounds like beta-caryophyllene also inhibit MGLL activity, increasing 2-AG levels in vivo. In cancer, NF-kB signaling can be modulated by MGLL activity, suggesting a feedback loop. Overall, regulation ensures that 2-AG levels are tightly controlled to maintain physiological balance.
monoacylglycerol lipase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MGLL | Prostate cancer, chemotherapy resistance | MGLL knockout prostate cancer cell lines; xenograft models |
| MGLL | Pain and inflammation | MGLL knockout mice; inhibitor-treated rodents |
| MGLL | Endocannabinoid signaling in brain | Brain-specific MGLL knockout mice; activity mapping |
| ABHD6 | Neuroinflammation | ABHD6 knockout mice; brain slice assays |
| ABHD12 | Neurodegenerative disease | ABHD12 knockout mice; patient-derived cells |
Monoacylglycerol lipase activity in cancer
In prostate cancer, monoacylglycerol lipase (MGLL) blockade suppresses the senescence-associated secretory phenotype (SASP) by interfering with NF-kB activation, and it promotes docetaxel efficacy. This suggests that inhibiting MGLL activity could be a therapeutic strategy to enhance chemotherapy response and reduce inflammation in tumors. MGLL expression is also elevated in other cancers, where it may support tumor growth and survival.
Monoacylglycerol lipase activity in pain and inflammation
Inhibiting monoacylglycerol lipase activity elevates 2-AG, which activates cannabinoid receptors and produces analgesia and anti-inflammatory effects in animal models. However, early inhibitors caused central side effects and dependence, prompting development of reversible inhibitors with improved safety profiles. Beta-caryophyllene, a dietary cannabinoid, inhibits MGLL activity and increases 2-AG levels in vivo, offering a potential natural analgesic mechanism.
Monoacylglycerol lipase activity in neurodegeneration
Monoacylglycerol lipase activity is critical for endocannabinoid signaling in the brain, and its dysregulation has been implicated in neurodegenerative and neuroinflammatory conditions. Spatially resolved mapping of activity in brain tissue reveals region-specific patterns that may relate to disease vulnerability. Modulating this activity could influence neuroinflammation and synaptic function, although further research is needed.
From monoacylglycerol lipase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of MGLL affect 2-AG levels and pain sensitivity? | MGLL knockout mouse |
| Can a point mutation in the catalytic serine abolish enzyme activity? | MGLL S122A point mutation knock-in cell line |
| Does tagging MGLL with a fluorescent protein alter its localization? | Knock-in of GFP-MGLL in cancer cells |
| Does overexpression of MGLL increase 2-AG degradation? | MGLL overexpression in neuronal cell lines |
| What is the effect of MGLL inhibition on docetaxel efficacy? | Prostate cancer xenografts with MGLL knockout or inhibitor |
| Can reversible inhibitors avoid central side effects? | MGLL inhibitor-treated mice; behavioral assays |
How to Study the monoacylglycerol lipase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiometric assay with [3H]-2-AG | Enzyme activity by detecting released fatty acid | In vitro inhibitor screening |
| Fluorogenic substrate assay | Hydrolysis rate via fluorescence | High-throughput screening |
| Activity-based protein profiling | Active enzyme levels in complex proteomes | Tissue mapping and target engagement |
| Mass spectrometry imaging | Spatial distribution of activity | Brain tissue mapping |
| Western blot | Protein expression levels | Validation of knockout or overexpression |
| qRT-PCR | mRNA expression | Gene expression analysis |
| CRISPR knockout | Loss of gene function | Phenotypic studies |
| In vivo behavioral assays | Pain and inflammation responses | Drug efficacy testing |
Measuring monoacylglycerol lipase activity in vitro
Enzyme activity can be measured using radiometric assays with [3H]-2-AG, fluorogenic substrates, or coupled enzyme systems that detect glycerol or fatty acid release. These assays are used to screen inhibitors and characterize enzyme kinetics. Detailed protocols are available for reproducible results.
Spatially resolved activity mapping
Activity-based protein profiling and mass spectrometry imaging allow mapping of monoacylglycerol lipase activity in tissue sections, revealing spatial patterns in the brain. This method uses activity-based probes that covalently label active enzymes, followed by detection.
Genetic manipulation and expression analysis
CRISPR knockout, point mutation, and overexpression models are used to study the function of MGLL and related genes. Expression levels can be quantified by qPCR, Western blot, and RNA-seq. These approaches help link genotype to enzyme activity and phenotype.
In vivo pharmacology and behavior
Inhibitors of monoacylglycerol lipase are administered to rodents to assess analgesic, anti-inflammatory, and central effects. Behavioral tests such as hot plate and formalin tests measure pain responses. Pharmacokinetic and dependence studies ensure safety.
How CRISPR Can Be Used to Study GO:0047372 monoacylglycerol lipase activity
Knockout
CRISPR knockout of MGLL or related genes eliminates monoacylglycerol lipase activity, allowing researchers to study its role in 2-AG signaling, pain, and cancer. Knockout cell lines and mice are valuable for target validation and drug discovery.
Point Mutation
Introducing point mutations in the catalytic triad of MGLL (e.g., S122A) abolishes enzyme activity without affecting protein expression, enabling precise structure-function studies. Such models help distinguish catalytic activity from non-catalytic functions.
Knock-in
Knock-in of tagged MGLL (e.g., GFP or HA) allows visualization and immunoprecipitation of the enzyme in live cells, facilitating localization and interaction studies. Knock-in of disease-associated mutations can model human conditions.
Overexpression
Overexpression of MGLL increases monoacylglycerol lipase activity, reducing 2-AG levels and altering endocannabinoid signaling. This approach is used to study downstream effects on cell proliferation, inflammation, and chemotherapy response.
How EDITGENE Supports monoacylglycerol lipase activity Research
Researchers studying monoacylglycerol lipase activity-related genes often need to determine whether a candidate gene is causally involved in lipid signaling, disease progression, or drug response. EDITGENE provides comprehensive CRISPR-based services to create precise cellular and animal models, enabling rigorous functional studies of GO:0047372 and its associated pathways.
Contact EDITGENE today to design your custom CRISPR model for monoacylglycerol lipase activity research.
Frequently Asked Questions About monoacylglycerol lipase activity
What is monoacylglycerol lipase activity?
Monoacylglycerol lipase activity (GO:0047372) is the enzymatic hydrolysis of a monoacylglycerol into a free fatty acid and glycerol, as defined by the Gene Ontology.
What genes are involved in monoacylglycerol lipase activity?
The primary gene is MGLL, but ABHD6 and ABHD12 also exhibit this activity. Other related genes include DAGLA, DAGLB, and FAAH.
How is monoacylglycerol lipase activity measured?
It can be measured using radiometric assays with [3H]-2-AG, fluorogenic substrates, or activity-based protein profiling.
What is the role of monoacylglycerol lipase in the endocannabinoid system?
It degrades 2-arachidonoylglycerol (2-AG), a major endocannabinoid, thereby terminating its signaling at cannabinoid receptors.
Can monoacylglycerol lipase inhibitors be used for pain?
Yes, inhibitors elevate 2-AG and produce analgesia in animal models, but early inhibitors had central side effects. Newer reversible inhibitors aim to avoid these.
Is monoacylglycerol lipase a cancer target?
In prostate cancer, MGLL blockade suppresses the senescence-associated secretory phenotype and improves docetaxel efficacy, suggesting it is a potential target.
What are the substrates of monoacylglycerol lipase?
The substrates are monoacylglycerols, including 2-arachidonoylglycerol (2-AG) and other monoacylglycerols.
Where is monoacylglycerol lipase located in the cell?
It is found in the cytosol, on membranes, and associated with lipid droplets, depending on the cell type.
What is the difference between MGLL and ABHD6?
Both hydrolyze monoacylglycerols, but MGLL is the primary enzyme for 2-AG degradation, while ABHD6 plays a more localized role in the brain.
How can CRISPR be used to study monoacylglycerol lipase activity?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of MGLL and related genes to study their function and drug response.
Conclusion
Monoacylglycerol lipase activity (GO:0047372) is a fundamental enzymatic function that regulates lipid signaling, particularly the endocannabinoid 2-AG. Its dysregulation is implicated in pain, inflammation, cancer, and neurodegeneration, making it a compelling therapeutic target. Advances in assay technology and CRISPR modeling continue to unravel its mechanisms and potential. Understanding this activity provides insights into lipid metabolism and offers opportunities for drug development and biotechnology.
References
- 1. Jung KM et al.. 2023. Assay of Monoacylglycerol Lipase Activity.. Methods Mol Biol 2576:285-297 PMID: 36152196
- 2. van der Vliet D et al.. 2025. Spatially Resolved Mapping of Monoacylglycerol Lipase Activity in the Brain.. ACS Chem Neurosci 16(24):4622-4635 PMID: 41313799
- 3. Liu X et al.. 2023. Monoacylglycerol lipase from marine Geobacillus sp. showing lysophospholipase activity and its application in efficient soybean oil degumming.. Food Chem 406:134506 PMID: 36463594
- 4. Jiang M et al.. 2023. A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence.. Nat Commun 14(1):8039 PMID: 38052772
- 5. Jiang M et al.. 2024. Structure-Activity Relationship Studies of Aryl Sulfoxides as Reversible Monoacylglycerol Lipase Inhibitors.. J Med Chem 67(14):12331-12348 PMID: 38988250
- 6. Jung KM et al.. 2016. Assay of Monoacylglycerol Lipase Activity.. Methods Mol Biol 1412:157-68 PMID: 27245902
- 7. Klawitter J et al.. 2024. β-Caryophyllene Inhibits Monoacylglycerol Lipase Activity and Increases 2-Arachidonoyl Glycerol Levels In Vivo: A New Mechanism of Endocannabinoid-Mediated Analgesia?. Mol Pharmacol 105(2):75-83 PMID: 38195158
- 8. Yu J et al.. 2024. Monoacylglycerol lipase blockades the senescence-associated secretory phenotype by interfering with NF-κB activation and promotes docetaxel efficacy in prostate cancer.. Oncogene 43(38):2835-2849 PMID: 39155296
